Expression of alpha-1,3-galactose and other type 2 oligosaccharide structures in a porcine endothelial cell line transfected with human alpha-1,2-fucosyltransferase cDNA.
The binding of xenoreactive natural antibodies to the Galalpha1-3Galbeta1-4GlcNAc (alpha-galactose) oligosaccharide epitope on pig cells activates the recipient's complement system in pig to primate xenotransplantation. Expression of human alpha-1, 2-fucosyltransferase in pigs has been proposed as a strategy for reducing the expression level of the alpha-galactose epitope, thereby rendering the pig organs more suitable for transplantation into humans. The aim of this study was to examine how the cell surface expression of alpha-galactose, H, and related fucosylated and sialylated structures on a pig liver endothelial cell line is affected by transfection of human alpha-1,2-fucosyltransferase cDNA. Nontransfected and mock-transfected cells expressed alpha-galactose, alpha-2,3-sialylated, and alpha-2,6-sialylated epitopes strongly, with low level expression of type 2 H and LewisX. By contrast, expression of the H epitope was increased 5-8-fold in transfected cells with a 40% reduction in the expression of alpha-galactose epitope and a 50% decrease in sialylation, as measured by binding of Maackia amurensis and Sambuccus nigra agglutinins. LewisX expression was reduced to background levels, while the LewisY neoepitope was induced in human alpha-1,2-fucosyltransferase-expressing pig cells. The activities of endogenous alpha-1,3-galactosyltransferase, alpha-1,3-fucosyltransferases, and alpha-2,3- and alpha-2, 6-sialyltransferases acting on lactosamine were unaffected. Our results show that a reduction in alpha-galactose epitope expression in porcine endothelial cells transfected with human alpha-1, 2-fucosyltransferase cDNA may be achieved but at the expense of considerable distortion of the overall cell surface glycosylation profile, including the appearance of carbohydrate epitopes that are absent from the parent cells.
Sepp
A
A
Department of Immunology, Royal Postgraduate Medical School, DuCane Road, London W12 0NN, United Kingdom.
Skacel
P
P
Lindstedt
R
R
Lechler
R I
RI
D000017:ABO Blood-Group System / Q000096:biosynthesis; D000818:Animals; D002460:Cell Line; D003001:Cloning, Molecular; D018076:DNA, Complementary; D004727:Endothelium / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D000939:Epitopes / Q000096:biosynthesis*; D005434:Flow Cytometry; D005647:Fucosyltransferases / Q000235:genetics / Q000378:metabolism*; D005697:Galactosides / Q000096:biosynthesis* / Q000276:immunology; D005818:Genetic Engineering / Q000379:methods; D006031:Glycosylation; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D037102:Lectins / Q000378:metabolism; D007983:Lewis Blood Group Antigens / Q000096:biosynthesis; D016256:Lewis X Antigen / Q000096:biosynthesis; D008099:Liver / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D008297:Male; D009844:Oligosaccharides / Q000096:biosynthesis* / Q000276:immunology; D011485:Protein Binding; D011994:Recombinant Proteins / Q000378:metabolism; D013552:Swine; D016378:Tissue Transplantation; D014162:Transfection; D014312:Trisaccharides / Q000096:biosynthesis* / Q000276:immunology; D000097631:Galactoside 2-alpha-L-fucosyltransferase
D000017:ABO Blood-Group System; D018076:DNA, Complementary; D000939:Epitopes; D005647:Fucosyltransferases; D005697:Galactosides; D007075:Immunoglobulin M; D037102:Lectins; D007983:Lewis Blood Group Antigens; D016256:Lewis X Antigen; D009844:Oligosaccharides; D011994:Recombinant Proteins; D014312:Trisaccharides; D000097631:Galactoside 2-alpha-L-fucosyltransferase; C094162:Lewis Y antigen; C076569:alpha-galactosyl epitope